In the treatment of Chronic sinusitis, medical needs are not ideally addressed, with 20% of  patients that do not respond to drug treatment. 

To address those needs, Dianosic develops an  Active Resorbable Intranasal Scaffold (ARIS) dedicated to chronic sinusitis sufferers after failure of conventional drug treatment. As it resorbs in the nasal cavity, the implant progressively releases a steroid to treat the sinus disease.

 

 

ARIS targets patients who underwent prior surgery or not, and can be placed without prior opening of the sinuses, and will remain active during 12 months, which multiplies by 4 treatment duration versus existing products on this market segment.

Long term (12 months) bioresorbable treatment

No prior surgical procedure required

100% treatment compliance (vs nasal sprays)

Optimized patient management